Category: Knees
Knees
A look at some of the news coming out of the 2011 Annual Meeting of the American Academy of Orthopaedic Surgeons.
"While you're down there, Doc..." A new study out of the University of California-Davis suggests that getting both knees replaced at the same time might be more effective then having separate procedures, although it might also kill you too.
A look at some of the news coming out of the 2011 Annual Meeting of the American Academy of Orthopaedic Surgeons.
A new study released this week showed that knee replacements are holding up remarkably well after two decades, with zero implant failures reported over the course of 20 years.
Stryker Corp. knee and hip implants demonstrate lower revision rates than competitors, according to the National Joint Registry for England and Wales.
Here's a roundup of recent clinical trial and scientific study news:
The British orthopedics giant Smith & Nephew plc signs tennis legend Billie Jean King to be spokeswoman for the company's Legion knee implants.
Smith & Nephew plc (NYSE:SNN) is going to see if Billie Jean King's pitch is as good as her serve.
The British orthopedics giant announced that the tennis legend has signed on as the company's spokeswoman for its Legion knee implants. King, who won six Wimbledon singles championships and four U.S. Open titles in a scintillating tennis career, had double knee replacement surgery last year using the Legion implant.
Smith and Nephew claims that the implants are built to provide 30 years of "active mobility under normal conditions."
ConforMIS Inc. lands 510(k) clearance from the Food & Drug Administration for its iTotal CR customized knee replacement system.
ConforMIS Inc. won 510(k) clearance from the Food & Drug Administration for its custom knee implant system, the iTotal CR.
Unlike standard implants, iTotal CR devices are based on an individual's CT scans and tailored for their knee bones using computer-aided design.
Standard implants come in six or seven different sizes, meaning that surgeons must measure a patient's bones after an incision to select the best fit, according to ConforMIS founder and CEO Philipp Lang.
Kensey Nash Corp. enters into a manufacturing agreement with Orteq Sports Medicine that includes an investment in the London-based medical device maker.
Kensey Nash Corp. (NSDQ:KNSY) entered into a manufacturing deal with London-based Orteq Sports Medicine that includes a minority equity investment in the company.
Orteq filed with the Food & Drug Administration for approval of a clinical trial on its Actifit bio-compatible synthetic meniscal repair scaffold, and if the agency approves the trial, Kensey Nash will invest an additional $1 million in Orteq. The device is already available in Europe.
ReGen Biologics Inc. and its CEO, Gerald Bisbee, fire back at the Food & Drug Administration over its decision to rescind a 2008 510(k) clearance granted to ReGen's Menaflex knee implant.
ReGen Biologics Inc. (OTC:RGBO) is firing back at the Food & Drug Administration after the federal watchdog agency said last week that it plans to rescind a 510(k) clearance for ReGen's controversial Menaflex knee implant.
